Cytokines News and Research

Latest Cytokines News and Research

Study to discover exactly how intravenous immune globulin treatments work

Immune globulin replacement began decades ago as a treatment for patients who could not make their own protective antibodies, but has proven to have much broader benefits than originally expected.

22 Nov 2012

IL-13 receptor system could play a major role in Parkinson's

Deciphering what causes the brain cell degeneration of Parkinson's disease has remained a perplexing challenge for scientists. But a team led by scientists from The Scripps Research Institute (TSRI) has pinpointed a key factor controlling damage to brain cells in a mouse model of Parkinson's disease.

20 Nov 2012

KLF4 genetic factor prevents blood vessels from blockages

Researchers at Case Western Reserve University School of Medicine have identified a genetic factor that prevents blockages from forming in blood vessels, a discovery that could lead to new therapies for cardiovascular diseases.

20 Nov 2012

Tregs appears to play an important role in suppressing immune response in advance of sepsis

Following an infection, dysregulation of the immune system can result in a systemic inflammatory response and an often fatal condition called severe sepsis or septic shock. Sepsis is not uncommon, yet its cause and underlying immune dysfunction remain poorly understood.

17 Nov 2012

Caterpillar fungi may benefit asthma patients

Research shows that cordycepin, extracted from a group of rare parasitic caterpillar fungi of the genus Cordyceps, has unusual anti-inflammatory properties that may make it a good candidate for treating conditions such as asthma and rheumatoid arthritis.

16 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Sea water therapy is a technique of cellular nutrition backed by more than 100 years of clinical use in hospitals, during which numerous studies have demonstrated its beneficial effects on patients' health.

29 Oct 2012

Study identifies genetic variations as predictors of prostate cancer-related fatigue

Researchers at Moffitt Cancer Center and the University of South Florida have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes. The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient's genetic profile.

29 Oct 2012

Psoriasis patients have high diabetes risk

People with psoriasis have an increased risk for developing Type 2 diabetes compared with people without the skin condition, suggest results from a systematic review and meta-analysis published in the Archives of Dermatology.

19 Oct 2012

Weill Cornell Medical College researcher wins 2012 William B. Coley Award

Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the 2012 William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute for her outstanding achievements in immunology and cancer research.

19 Oct 2012

Cytokine levels altered in FEP, schizophrenia patients

Levels of certain cytokines are altered in patients with first-episode psychosis and patients with schizophrenia, research shows.

17 Oct 2012

Companionship can reduce nerve-related pain

Companionship has the potential to reduce pain linked to nerve damage, according to a new study.

16 Oct 2012

Rheumatoid arthritis treatment foiled by gum disease

Periodontal disease may reduce the efficacy of tumor necrosis factor inhibitor treatment in patients with rheumatoid arthritis, preliminary research suggests.

15 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.

15 Oct 2012

Curcumin can inhibit formation of prostate cancer metastases

Powdered turmeric has been used for centuries to treat osteoarthritis and other illnesses. Its active ingredient, curcumin, inhibits inflammatory reactions. A new study led by a research team at Ludwig-Maximilians-Universit-t (LMU) in Munich now shows that it can also inhibit formation of metastases.

13 Oct 2012

Researchers discover mechanism by which magnesium reduces cytokine production

Magnesium sulfate is given to many pregnant women to treat preterm labor and preeclampsia and was recently shown to prevent cerebral palsy; however little is known about how it works. Researchers at Case Western Reserve University School of Medicine recently discovered the mechanism by which magnesium reduces the production of cytokines.

10 Oct 2012

Fertility treatment may increase MS disease activity

Findings published in Annals of Neurology suggest that assisted reproduction technology treatment increases multiple sclerosis disease activity.

8 Oct 2012

Assisted reproduction technology may increase risk of MS activity among women

Researchers in Argentina report that women with multiple sclerosis (MS) who undergo assisted reproduction technology (ART) infertility treatment are at risk for increased disease activity.

4 Oct 2012

Positive data from three Onconova Ex-RAD clinical trials on acute radiation syndrome

Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).

4 Oct 2012